As the U.S. flu season winds down, health officials say the flu vaccine didn’t work very well. It had one of its worst effectiveness rates in more than a decade.

FDA advisers recommend fall flu shot changes to include the new subclade K H3N2 variant for the 2026-27 season, improving vaccine relevance.

–Public Health officials across the country are reemphasizing the importance of seasonal influenza vaccines as peak flu season comes to an end. Cede Becker is a Registered Nurse in the Community ...

KENTUCKY, USA — Flu cases are on the rise once again this winter, and doctors say more kids are catching the virus. Overall, this is the second straight winter that medical experts say flu numbers ...

For the past week, about 50 flu scientists from around the world were crammed into a conference room at a Hilton hotel in Istanbul, Turkey. Their goal was to design a flu shot that will confer the ...

President Trump’s nominee for surgeon general aligned herself with the administration’s moves on vaccines so far, including shrinking the number of recommended vaccines for children, as she told ...

Health Secretary Robert F. Kennedy Jr. has spent years campaigning against vaccines, but with the flu shot, he’s suggested it’s personal. Kennedy has linked his strained, raspy speech to the vaccine, ...

The Food and Drug Administration agreed Wednesday to review Moderna’s application to make a new seasonal flu shot available, after initially refusing to do so. The back-and-forth reveals increased ...

WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of ...

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a ...

The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, company and federal officials said ...